PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.
about
Endothelial-Leukocyte Interaction in Severe Malaria: Beyond the BrainVascular dysfunction as a target for adjuvant therapy in cerebral malariaThe neurotrophic receptor Ntrk2 directs lymphoid tissue neovascularization during Leishmania donovani infectionSafety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malariaSjCa8, a calcium-binding protein from Schistosoma japonicum, inhibits cell migration and suppresses nitric oxide release of RAW264.7 macrophages.Pathogenesis of cerebral malaria: new diagnostic tools, biomarkers, and therapeutic approaches.Complement Activation in Placental Malaria.Supplementation with Abscisic Acid Reduces Malaria Disease Severity and Parasite Transmission.Systematic review of the role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic targets?miR-155 Modifies Inflammation, Endothelial Activation and Blood-Brain Barrier Dysfunction in Cerebral Malaria.The immunological balance between host and parasite in malaria.Peroxisome proliferator activating receptor-γ and the podocyte.A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration.Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria.Adjunctive therapy for severe malaria: a review and critical appraisal.Endothelial Activation: The Ang/Tie Axis in Sepsis.Oxidative Stress: A Potential Therapeutic Target in Placental Malaria
P2860
Q26778543-4800737C-FFB4-4689-8FDE-C4E7825B0431Q27025436-8174EF1B-DDF8-4108-BA09-02486F8FA6AEQ27321179-59812FAC-97C8-4D44-B714-79ECE8370490Q33721892-7AC1B5BA-66A0-41A0-9E59-01946412806CQ36135568-A1BAE5CA-046D-41AB-80D9-2296A3F0CA04Q36209383-C3A38E74-CF95-40BA-B8A8-70C2FC1111FDQ36387332-8F09201B-EE15-46FD-A6DB-236EFA53C7B9Q36958477-9117503D-7E99-48C6-BE17-078AD641F301Q37466271-6C610DD8-F66A-4B6C-A71F-CCD923C865F5Q37718931-D4AD47FE-3068-4FC1-B7E9-8A55717D0FEAQ38666558-7D301A39-F111-4FD0-BEC5-3C6A8FA513C7Q38815188-379CD217-B75E-4A45-BBB0-2F1FB129AC41Q45330025-C395934D-A740-412E-BB74-3A26CC97CED6Q47093575-F488D3D4-1D4A-4821-B025-CE00D7BF7A82Q47716363-B2CDD230-D74D-4FC5-A833-7A529150A2E4Q54217602-D578C530-0166-446E-85DE-C55CD9ABE118Q56435439-6F72732E-C2A8-44C3-A454-83EF6E6F97D8
P2860
PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@ast
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@en
type
label
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@ast
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@en
prefLabel
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@ast
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@en
P2093
P2860
P50
P1433
P1476
PPARγ agonists improve surviva ...... ive pathways in human malaria.
@en
P2093
Cheryl Cui
Chloe R McDonald
Howard T J Mount
Keith T Ho
Miriam Friedel
P2860
P304
P356
10.1371/JOURNAL.PPAT.1003980
P577
2014-03-06T00:00:00Z